Autologous hematopoietic stem cell transplant (HSCT) is a standard treatment for multiple myeloma (MM).1 It is well known that kidney dysfunction related to MM, either acute or chronic, may be multifactorial, with factors including cast nephropathy and other paraprotein-associated renal diseases, nephrotoxicity owing to chemotherapy, immunosuppressive agents, and direct infiltration of neoplastic cells, among others. Furthermore, HSCT per se adds additional risks of developing kidney dysfunction with issues related to nephrotoxicity from medications, thrombotic microangiopathy, graft-versus-host disease (GVHD), and increased risk of infectious diseases.